Synergy Empire Limited (SHMY) has completed the acquisition of Meluha Therapeutics Berhad, a Malaysian biopharmaceutical company. The acquisition was finalized on March 28, 2025, with SHMY issuing 10,000,000 shares of Series A preferred stock, valued at $0.2155 per share, for an aggregate value of $2,155,000. This transaction shifts Synergy Empire's business focus from the food and beverage industry to the healthcare and pharmaceutical sector. Meluha Therapeutics specializes in contract manufacturing for cellular therapy, drug discovery, and related research and development, utilizing stem cell technology. Following the acquisition, two former Meluha shareholders, Ramesh A/L Saravanamuthu and Abdul Jalil bin Jidon, now hold significant voting power in Synergy Empire, controlling approximately 29.1% and 27.7% respectively, enabling them to unilaterally control the board of directors and company direction.